Gossamer Bio: Wedbush cuts target price to $32 from $80
GOSS•Wedbush cut its target price for Gossamer Bio to $32 from $80.
Related News
Merlin wins $500,000 U.S. Africa Command contract for autonomous casualty evacuation demo
MRLN•
Nayax Q3 2026 swings to $1.08 million net loss as revenue rises 23% to $128.04 million
NYAX•
PolyPid Q3 net loss narrows 23% to $5.75 million
PYPD•
Wells Fargo cuts Bain Capital Specialty Finance target price to $11 from $12
BCSF•
Vertiv Holdings Co: JP Morgan resumes coverage with neutral rating; target price $240
VRT•